Raf激酶抑制蛋白与肿瘤

Raf激酶抑制蛋白(Raf kinase inhibitor protein,RKIP)是磷酯酰乙醇胺结合蛋白家族的成员。RKIP在Raf、核因子κB及G蛋白耦联受体(GPCR)等蛋白激酶信号转导通路中起重要调节作用。RKIP在膜的生物合成、精子发生、神经发育和细胞凋亡等生理过程中发挥重要作用,并参与了老年痴呆症及糖尿病等的病理过程。近年来研究表明,RKIP在多种恶性肿瘤中表达减弱或丢失,且RKIP可以抑制前列腺癌、人乳腺癌和黑色素瘤细胞的转移,其在恶性肿瘤中作用机制已经成为研究的热点。RKIP与肿瘤的研究将为肿瘤治疗提供新的靶点,本文就此研究状况予以简要综述。

Raf Kinase Inhibitor Protein and Tumors

Raf kinase inhibitor protein （RKIP） is a member of the phosphatidylethano lamine-binding protein family. RKIP blocks Raf-indueed phosphorylation of mitogen-activated protein Kinase kinases （MEK）. In addition to its modulation of Raf signaling, RKIP modulates both G-protein signaling and NF-κB activity. RKIP plays a critical role in several physiological processes including membrane biosynthesis, spermatogenesis, neural development and apoptosis. It also contributes to pathophysiological processes including Alzheimer＇s disease and diabetic nephropathy. Recent researches show RKIP levels are found to be reduced or lost in many malignant tumors, Additionally, related researches showed RKIP is a novel metastasis suppressor,which suppresses metastasis in prostate cancer, breast cancer and melanoma cancer., what is more, its mechanism of action in malignant tumor has become the hot spot. The research about RKIP and tumor will provide new targer for tumor therapy. This article reviewed progresses.